FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366168944> ?p ?o ?g. }

• W4366168944 endingPage "34" @default.
• W4366168944 startingPage "26" @default.
• W4366168944 abstract "Vericiguat and its metabolite M-1 were assessed for proarrhythmic risk in nonclinical <i>in vitro</i> and <i>in vivo</i> studies. <i>In vitro</i> manual voltage-clamp recordings at room temperature determined the effect of vericiguat on human Ether-a-go-go Related Gene (hERG) K⁺ channels. Effects of vericiguat and M-1 on hERG K⁺, Nav1.5, hCav1.2, hKvLQT1/1minK, and hKv4.3 channels were investigated via automated voltage-clamp recordings at ambient temperature. Effects of vericiguat and M-1 on hERG K⁺ and Nav1.5 channels at pathophysiological conditions were explored via manual voltage-clamp recordings at physiological temperature. Single oral doses of vericiguat (0.6, 2.0, and 6.0 mg/kg) were assessed for <i>in vivo</i> proarrhythmic risk via administration to conscious telemetered dogs; electrocardiogram (ECG) and hemodynamic parameters were monitored. ECG recordings were included in 4- and 39-week dog toxicity studies. In manual voltage-clamp recordings, vericiguat inhibited hERG K⁺-mediated tail currents in a concentration-dependent manner (20% threshold inhibitory concentration ~1.9 µM). In automated voltage-clamp recordings, neither vericiguat nor M-1 were associated with biologically relevant inhibition (>20%) of hNav1.5, hCav1.2, hKvLQT1, and hKv4.3. No clinically relevant observations were made for hNav1.5 and hKvLQT1 under simulated pathophysiological conditions. Vericiguat was associated with expected mode-of-action-related dose-dependent changes in systolic arterial blood pressure (up to −20%) and heart rate (up to +53%). At maximum vericiguat dose, corrected QT (QTc) interval changes from baseline varied slightly (−6 to +1%) depending on correction formula. Toxicity studies confirmed absence of significant QTc interval changes. There was no evidence of increased proarrhythmic risk from nonclinical studies with vericiguat or M-1. <b>Significance Statement</b> There was no evidence of increased proarrhythmic risk from <i>in vitro</i> and <i>in vivo</i> nonclinical studies with vericiguat or M-1. The integrated risk assessment of these nonclinical data combined with existing clinical data demonstrate administration of vericiguat 10 mg once daily in patients with heart failure with reduced ejection fraction is not associated with a proarrhythmic risk." @default.
• W4366168944 created "2023-04-19" @default.
• W4366168944 creator A5001865997 @default.
• W4366168944 creator A5021424606 @default.
• W4366168944 creator A5025305814 @default.
• W4366168944 creator A5039396759 @default.
• W4366168944 creator A5045441577 @default.
• W4366168944 creator A5058232292 @default.
• W4366168944 creator A5061627667 @default.
• W4366168944 creator A5070883929 @default.
• W4366168944 creator A5091026533 @default.
• W4366168944 date "2023-04-17" @default.
• W4366168944 modified "2023-10-01" @default.
• W4366168944 title "Nonclinical Cardiovascular Assessment of the Soluble Guanylate Cyclase Stimulator Vericiguat" @default.
• W4366168944 cites W1969338470 @default.
• W4366168944 cites W1984400720 @default.
• W4366168944 cites W1984775204 @default.
• W4366168944 cites W1989217478 @default.
• W4366168944 cites W2003783126 @default.
• W4366168944 cites W2027665464 @default.
• W4366168944 cites W2042007807 @default.
• W4366168944 cites W2045404896 @default.
• W4366168944 cites W2045498573 @default.
• W4366168944 cites W2085048839 @default.
• W4366168944 cites W2090159456 @default.
• W4366168944 cites W2090696765 @default.
• W4366168944 cites W2095627701 @default.
• W4366168944 cites W2113927644 @default.
• W4366168944 cites W2126112930 @default.
• W4366168944 cites W2148274682 @default.
• W4366168944 cites W2169197323 @default.
• W4366168944 cites W2328454508 @default.
• W4366168944 cites W2338387536 @default.
• W4366168944 cites W2588081908 @default.
• W4366168944 cites W2734625065 @default.
• W4366168944 cites W2755193453 @default.
• W4366168944 cites W2790950004 @default.
• W4366168944 cites W2803700865 @default.
• W4366168944 cites W3003963028 @default.
• W4366168944 cites W3013207865 @default.
• W4366168944 cites W3025173075 @default.
• W4366168944 cites W3109792671 @default.
• W4366168944 cites W3184967113 @default.
• W4366168944 cites W3193598686 @default.
• W4366168944 cites W3204992837 @default.
• W4366168944 cites W4233306427 @default.
• W4366168944 doi "https://doi.org/10.1124/jpet.122.001368" @default.
• W4366168944 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37068911" @default.
• W4366168944 hasPublicationYear "2023" @default.
• W4366168944 type Work @default.
• W4366168944 citedByCount "1" @default.
• W4366168944 countsByYear W43661689442023 @default.
• W4366168944 crossrefType "journal-article" @default.
• W4366168944 hasAuthorship W4366168944A5001865997 @default.
• W4366168944 hasAuthorship W4366168944A5021424606 @default.
• W4366168944 hasAuthorship W4366168944A5025305814 @default.
• W4366168944 hasAuthorship W4366168944A5039396759 @default.
• W4366168944 hasAuthorship W4366168944A5045441577 @default.
• W4366168944 hasAuthorship W4366168944A5058232292 @default.
• W4366168944 hasAuthorship W4366168944A5061627667 @default.
• W4366168944 hasAuthorship W4366168944A5070883929 @default.
• W4366168944 hasAuthorship W4366168944A5091026533 @default.
• W4366168944 hasBestOaLocation W43661689441 @default.
• W4366168944 hasConcept C100837961 @default.
• W4366168944 hasConcept C126322002 @default.
• W4366168944 hasConcept C127413603 @default.
• W4366168944 hasConcept C147944092 @default.
• W4366168944 hasConcept C150903083 @default.
• W4366168944 hasConcept C185263204 @default.
• W4366168944 hasConcept C185592680 @default.
• W4366168944 hasConcept C207001950 @default.
• W4366168944 hasConcept C2776161997 @default.
• W4366168944 hasConcept C2776190711 @default.
• W4366168944 hasConcept C2777151030 @default.
• W4366168944 hasConcept C2777953023 @default.
• W4366168944 hasConcept C2779362680 @default.
• W4366168944 hasConcept C2780035454 @default.
• W4366168944 hasConcept C71924100 @default.
• W4366168944 hasConcept C78519656 @default.
• W4366168944 hasConcept C83743174 @default.
• W4366168944 hasConcept C84111939 @default.
• W4366168944 hasConcept C84393581 @default.
• W4366168944 hasConcept C86803240 @default.
• W4366168944 hasConcept C98274493 @default.
• W4366168944 hasConceptScore W4366168944C100837961 @default.
• W4366168944 hasConceptScore W4366168944C126322002 @default.
• W4366168944 hasConceptScore W4366168944C127413603 @default.
• W4366168944 hasConceptScore W4366168944C147944092 @default.
• W4366168944 hasConceptScore W4366168944C150903083 @default.
• W4366168944 hasConceptScore W4366168944C185263204 @default.
• W4366168944 hasConceptScore W4366168944C185592680 @default.
• W4366168944 hasConceptScore W4366168944C207001950 @default.
• W4366168944 hasConceptScore W4366168944C2776161997 @default.
• W4366168944 hasConceptScore W4366168944C2776190711 @default.
• W4366168944 hasConceptScore W4366168944C2777151030 @default.
• W4366168944 hasConceptScore W4366168944C2777953023 @default.
• W4366168944 hasConceptScore W4366168944C2779362680 @default.
• W4366168944 hasConceptScore W4366168944C2780035454 @default.

• next